Bellus Health closes $35 mln financing led by OrbiMed
Laval, Québec-based clinical-stage biopharmaceutical company Bellus Health Inc (TSX: BLU) has secured $35 million in an equity offering. The offering was led by U.S. healthcare investment firm OrbiMed. New Leaf Venture Partners, First Manhattan Co, Samsara BioCapital, Fonds de solidarité FTQ, AppleTree Partners and Amzak Health also participated. OrbiMed Partner Chau Khuong has joined the board. The proceeds will be used to advance the company's lead drug candidate, BLU-5937, for chronic cough. A Phase 2 study will be initiated in mid-2019. Bellus is led by President and CEO Roberto Bellini.
18 December 2018•5 mins read
